Use of polysaccharide for treating ST-elevation myocardial infarction and diseases of the digestion system
AssigneePT. Sahabat Lingkungan Hidup
InventorsPeter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using β-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising β-1,3/1,6-D-glucan are also provided.
Claims17
A method of treating a disease of the digestive system in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, wherein the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, has been substantially isolated from Ganoderma lucidum mycelium;
- and
- wherein the method further comprises identifying or having identified the subject as exhibiting abnormal expression of one or more cytokines, and wherein the effective amount is obtained by measuring the expression change of interleukin-6, tumor necrosis factor-α, and C-reactive protein between pre- and post-administration of the β-1,3/1,6-D-glucan.
A method of treating a disease of the digestive system in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, wherein the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, has been substantially isolated from Ganoderma lucidum mycelium;
- and
- wherein the method further comprises identifying or having identified the subject as exhibiting abnormal expression of one or more cytokines, and wherein the effective amount is obtained by measuring the expression change of interleukin-6, tumor necrosis factor-α, and C-reactive protein between pre- and post-administration of the β-1,3/1,6-D-glucan.
A method of treating one or more symptoms of a disease of the digestive system in a subject in need thereof, comprising:
- a) identifying or having identified a subject as exhibiting one or more symptoms of the disease of the digestive system;
- and b) administering to the subject a therapeutically effective amount of β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, wherein the β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, has been substantially isolated from Ganoderma lucidum mycelium;
- and
- wherein the method further comprises identifying or having identified the subject as exhibiting abnormal expression of one or more cytokines, and wherein the effective amount is obtained by measuring the expression change of interleukin-6, tumor necrosis factor-α, and C-reactive protein between pre- and post-administration of the β-1,3/1,6-D-glucan.
A method of treating one or more symptoms of a disease of the digestive system in a subject in need thereof, comprising:
- a) identifying or having identified a subject as exhibiting one or more symptoms of the disease of the digestive system;
- and b) administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising β-1,3/1,6-D-glucan, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients;
- and
- wherein the method further comprises identifying or having identified the subject as exhibiting abnormal expression of one or more cytokines, and wherein the effective amount is obtained by measuring the expression change of interleukin-6, tumor necrosis factor-α, and C-reactive protein between pre- and post-administration of the β-1,3/1,6-D-glucan.
Dependencies are inferred from the claim text.